{"nctId":"NCT01507831","briefTitle":"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","startDateStruct":{"date":"2012-01"},"conditions":["Hypercholesterolemia"],"count":2341,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo (for alirocumab)","Drug: Lipid-Modifying Therapy (LMT)"]},{"label":"Alirocumab","type":"EXPERIMENTAL","interventionNames":["Drug: Alirocumab","Drug: Lipid-Modifying Therapy (LMT)"]}],"interventions":[{"name":"Placebo (for alirocumab)","otherNames":[]},{"name":"Alirocumab","otherNames":["SAR236553","REGN727","Praluent"]},{"name":"Lipid-Modifying Therapy (LMT)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nEither A or B below and who were not adequately controlled with their lipid-modifying therapy:\n\nA) Participants with heterozygous familial hypercholesterolemia (heFH) with or without established coronary heart disease (CHD) or CHD risk equivalents\n\nOR\n\nB) Participants with hypercholesterolemia together with established CHD or CHD risk equivalents.\n\nExclusion criteria:\n\n* Age \\< 18 years\n* LDL-C \\<70 mg/dL (\\< 1.81 mmol/L)\n* Fasting serum triglycerides \\> 400 mg/dL (\\>4.52 mmol/L)\n\nThe above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Who Experienced Adverse Events (AEs)","description":"Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'treatment-emergent period' (the time from the first dose of study drug up to the last dose of study drug +70 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":null},{"groupId":"OG001","value":"81.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.5","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"7.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis","description":"Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were used in the model (ITT analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.0"},{"groupId":"OG001","value":"-61.0","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection) (on-treatment analysis).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.0"},{"groupId":"OG001","value":"-62.8","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.0"},{"groupId":"OG001","value":"-63.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.0"},{"groupId":"OG001","value":"-64.2","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Measured LDL-C at Week 24 - ITT Analysis","description":"Measured LDL-C values via beta quantification method. Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"1.1"},{"groupId":"OG001","value":"-57.8","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.0"},{"groupId":"OG001","value":"-52.8","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.9"},{"groupId":"OG001","value":"-54.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.9"},{"groupId":"OG001","value":"-51.6","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.9"},{"groupId":"OG001","value":"-53.1","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.7"},{"groupId":"OG001","value":"-37.8","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo B at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.9"},{"groupId":"OG001","value":"-55.5","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.8"},{"groupId":"OG001","value":"-53.7","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.6"},{"groupId":"OG001","value":"-38.8","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High Cardiovascular (CV) Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis","description":"Very high CV risk: Heterozygous Familial Hypercholesterolemia (heFH) participants with coronary heart disease (CHD) or CHD risk equivalents or non- Familial Hypercholesterolemia (FH). High CV risk: heFH participants without CHD or CHD risk equivalents. CHD risk equivalent: peripheral arterial disease, ischemic stroke, moderate chronic kidney disease (estimated glomerular filtration rate, 30 to \\<60 ml/minute/1.73 m\\^2 of body-surface area), or diabetes mellitus plus 2 or more additional risk factors (hypertension; ankle-brachial index of â‰¤0.90; microalbuminuria, macroalbuminuria, or a urinary dipstick result of \\>2+ protein; preproliferative or proliferative retinopathy or laser treatment for retinopathy; or family history of premature CHD). Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"80.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":null},{"groupId":"OG001","value":"82.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis","description":"Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"79.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis","description":"Adjusted percentages at Week 24 from multiple imputation approach model including available post-baseline data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0","spread":null},{"groupId":"OG001","value":"81.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment were included in the imputation model.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"1.0"},{"groupId":"OG001","value":"-29.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.5"},{"groupId":"OG001","value":"4.0","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis","description":"Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"1.2"},{"groupId":"OG001","value":"-15.6","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"0.6"},{"groupId":"OG001","value":"4.0","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"1.0"},{"groupId":"OG001","value":"-28.2","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.5"},{"groupId":"OG001","value":"5.8","spread":"0.4"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis","description":"Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 52 regardless of status on-or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.1"},{"groupId":"OG001","value":"-16.7","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.5"},{"groupId":"OG001","value":"4.6","spread":"0.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 52 from MMRM model including all available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"1.2"},{"groupId":"OG001","value":"-56.8","spread":"0.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"1.1"},{"groupId":"OG001","value":"-59.9","spread":"0.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 78 - ITT Analysis","description":"Adjusted LS means and standard errors at Week 78 from MMRM model including all available post-baseline data from Week 4 to Week 78 regardless of status on- or off-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"1.3"},{"groupId":"OG001","value":"-52.4","spread":"0.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Calculated LDL-C at Week 78 - On-Treatment Analysis","description":"Adjusted LS means and standard errors at Week 78 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 78 (i.e. up to 21 days after last injection).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"1.2"},{"groupId":"OG001","value":"-58.0","spread":"0.9"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Who Experienced Cardiovascular (CV) Events","description":"CV events included coronary heart disease (CHD) death; non-fatal myocardial infarction (MI); fatal and non-fatal ischemic stroke; unstable angina requiring hospitalization; congestive heart failure (CHF) requiring hospitalization; ischemia-driven coronary revascularization procedure. Reported events are CV events as confirmed by an independent Clinical Events Committee (CEC) that occurred during the treatment emergent period ( i.e. from first dose up to the last dose of study drug + 70 days).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"POST_HOC","title":"Percentage of Participants Who Experienced Major Adverse CV Events","description":"Major adverse CV events were defined as all adverse CV events except Congestive heart failure (CHF) requiring hospitalization; and ischemia-driven coronary revascularization procedure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":154,"n":788},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Back pain","Diarrhoea"]}}}